GlassScriptPhysician profile
Kimberly Mccabe
NPI 1104247360
$4,757.59
in general payments reported to CMS, 2019-2025
24 companies · $2,108 in 2025
The $2,108 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $1,493 · 2024: $1,030 · 2025: $2,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,629.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.78 | 2023-2025 | |
| Dexcom, INC. | $384.95 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Neurocrine Biosciences, INC. | $374.16 | 2023-2025 | Ingrezza |
| Abiomed | $302.34 | 2024-2025 | Impella |
| Sanofi Pasteur INC. | $272.41 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $268.86 | 2024-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $234.33 | 2025 | Watchman Flx, Watchman Access System |
| Genzyme Corporation | $220.60 | 2023 | |
| Novo Nordisk INC | $216.58 | 2023-2025 | Ozempic, Wegovy |
| Arcutis Biotherapeutics, INC. | $186.46 | 2023-2024 | Zoryve |
| Abbott Laboratories | $175.31 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $138.98 | 2024 | |
| Cvrx, INC. | $137.79 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $127.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.85 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $115.75 | 2025 | Vyvgart |
| Amgen INC. | $115.22 | 2025 | |
| Alkermes, INC. | $114.75 | 2023 | Lybalvi |
| Paratek Pharmaceuticals, INC. | $113.72 | 2025 | Nuzyra |
| Insmed, INC. | $105.30 | 2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $95.63 | 2025 | Airsupra |
| Idorsia Pharmaceuticals US INC | $62.40 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $39.87 | 2024 | Trelegy Ellipta |
| Pfizer INC. | $14.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.